Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variant

doi:10.1016/j.ejim.2023.03.027

. 2023 Jun:112:128-132.

doi: 10.1016/j.ejim.2023.03.027. Epub 2023 Mar 29.

Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variant

Martina Zappa¹, Paolo Verdecchia², Fabio Angeli³

Affiliations

¹ Department of Medicine and Surgery, University of Insubria, Varese, Italy.
² Fondazione Umbra Cuore e Ipertensione-ONLUS and Division of Cardiology, Hospital S. Maria della Misericordia, Perugia, Italy.
³ Department of Medicine and Surgery, University of Insubria, Varese, Italy; Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Italy. Electronic address: fabio.angeli@uninsubria.it.

PMID: 37005200
PMCID: PMC10050278
DOI: 10.1016/j.ejim.2023.03.027

Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variant

Martina Zappa et al. Eur J Intern Med. 2023 Jun.

. 2023 Jun:112:128-132.

doi: 10.1016/j.ejim.2023.03.027. Epub 2023 Mar 29.

Authors

Martina Zappa¹, Paolo Verdecchia², Fabio Angeli³

Affiliations

¹ Department of Medicine and Surgery, University of Insubria, Varese, Italy.
² Fondazione Umbra Cuore e Ipertensione-ONLUS and Division of Cardiology, Hospital S. Maria della Misericordia, Perugia, Italy.
³ Department of Medicine and Surgery, University of Insubria, Varese, Italy; Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Italy. Electronic address: fabio.angeli@uninsubria.it.

PMID: 37005200
PMCID: PMC10050278
DOI: 10.1016/j.ejim.2023.03.027

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The Authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Cited by

Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies.
Faraji N, Zeinali T, Joukar F, Aleali MS, Eslami N, Shenagari M, Mansour-Ghanaei F. Faraji N, et al. Heliyon. 2024 Apr 25;10(9):e30208. doi: 10.1016/j.heliyon.2024.e30208. eCollection 2024 May 15. Heliyon. 2024. PMID: 38707429 Free PMC article. Review.
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.
Chang-Rabley E, van Zelm MC, Ricotta EE, Edwards ESJ. Chang-Rabley E, et al. Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675. Vaccines (Basel). 2024. PMID: 38932404 Free PMC article. Review.
Genomic Surveillance of SARS-CoV-2 in Malaysia during the Era of Endemic COVID-19.
Lee TY, Lim WF, Ang GY, Yu CY. Lee TY, et al. Life (Basel). 2023 Jul 28;13(8):1644. doi: 10.3390/life13081644. Life (Basel). 2023. PMID: 37629505 Free PMC article.

References

1. Telenti A., Hodcroft E.B., Robertson D.L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12 doi: 10.1101/cshperspect.a041390. - DOI - PMC - PubMed
1. Zappa M., Verdecchia P., Angeli F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): a simulation study. Eur. J. Intern. Med. 2022;105:107–108. - PMC - PubMed
1. Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., Zepeda S.K., Papa G., Kemp S.A., Ikeda T., Toyoda M., Tan T.S., Kuramochi J., Mitsunaga S., Ueno T., Shirakawa K., Takaori-Kondo A., Brevini T., Mallery D.L., Charles O.J., Bowen J.E., Joshi A., Walls A.C., Jackson L., Martin D., Smith K.G.C., Bradley J., Briggs J.A.G., Choi J., Madissoon E., Meyer K.B., Mlcochova P., Ceron-Gutierrez L., Doffinger R., Teichmann S.A., Fisher A.J., Pizzuto M.S., de Marco A., Corti D., Hosmillo M., Lee J.H., James L.C., Thukral L., Veesler D., Sigal A., Sampaziotis F., Goodfellow I.G., Matheson N.J., Sato K., Gupta R.K. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. - PMC - PubMed
1. Lyke K.E., Atmar R.L., Islas C.D., Posavad C.M., Szydlo D., Paul Chourdhury R., Deming M.E., Eaton A., Jackson L.A., Branche A.R., El Sahly H.M., Rostad C.A., Martin J.M., Johnston C., Rupp R.E., Mulligan M.J., Brady R.C., Frenck R.W., Jr., Bäcker M., Kottkamp A.C., Babu T.M., Rajakumar K., Edupuganti S., Dobrzynski D., Coler R.N., Archer J.I., Crandon S., Zemanek J.A., Brown E.R., Neuzil K.M., Stephens D.S., Post D.J., Nayak S.U., Suthar M.S., Roberts P.C., Beigel J.H., Montefiori D.C. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep. Med. 2022;3 - PMC - PubMed
1. Parums D.V. Editorial: world health organization (WHO) variants of concern lineages under monitoring (VOC-LUM) in response to the global spread of lineages and sublineages of Omicron, or B.1.1.529, SARS-CoV-2. Med. Sci. Monit. 2022;28 international medical journal of experimental and clinical research. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Telenti A., Hodcroft E.B., Robertson D.L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12 doi: 10.1101/cshperspect.a041390. - DOI - PMC - PubMed

[2] Telenti A., Hodcroft E.B., Robertson D.L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12 doi: 10.1101/cshperspect.a041390. - DOI - PMC - PubMed

[3] Zappa M., Verdecchia P., Angeli F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): a simulation study. Eur. J. Intern. Med. 2022;105:107–108. - PMC - PubMed

[4] Zappa M., Verdecchia P., Angeli F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): a simulation study. Eur. J. Intern. Med. 2022;105:107–108. - PMC - PubMed

[5] Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., Zepeda S.K., Papa G., Kemp S.A., Ikeda T., Toyoda M., Tan T.S., Kuramochi J., Mitsunaga S., Ueno T., Shirakawa K., Takaori-Kondo A., Brevini T., Mallery D.L., Charles O.J., Bowen J.E., Joshi A., Walls A.C., Jackson L., Martin D., Smith K.G.C., Bradley J., Briggs J.A.G., Choi J., Madissoon E., Meyer K.B., Mlcochova P., Ceron-Gutierrez L., Doffinger R., Teichmann S.A., Fisher A.J., Pizzuto M.S., de Marco A., Corti D., Hosmillo M., Lee J.H., James L.C., Thukral L., Veesler D., Sigal A., Sampaziotis F., Goodfellow I.G., Matheson N.J., Sato K., Gupta R.K. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. - PMC - PubMed

[6] Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., Zepeda S.K., Papa G., Kemp S.A., Ikeda T., Toyoda M., Tan T.S., Kuramochi J., Mitsunaga S., Ueno T., Shirakawa K., Takaori-Kondo A., Brevini T., Mallery D.L., Charles O.J., Bowen J.E., Joshi A., Walls A.C., Jackson L., Martin D., Smith K.G.C., Bradley J., Briggs J.A.G., Choi J., Madissoon E., Meyer K.B., Mlcochova P., Ceron-Gutierrez L., Doffinger R., Teichmann S.A., Fisher A.J., Pizzuto M.S., de Marco A., Corti D., Hosmillo M., Lee J.H., James L.C., Thukral L., Veesler D., Sigal A., Sampaziotis F., Goodfellow I.G., Matheson N.J., Sato K., Gupta R.K. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. - PMC - PubMed

[7] Lyke K.E., Atmar R.L., Islas C.D., Posavad C.M., Szydlo D., Paul Chourdhury R., Deming M.E., Eaton A., Jackson L.A., Branche A.R., El Sahly H.M., Rostad C.A., Martin J.M., Johnston C., Rupp R.E., Mulligan M.J., Brady R.C., Frenck R.W., Jr., Bäcker M., Kottkamp A.C., Babu T.M., Rajakumar K., Edupuganti S., Dobrzynski D., Coler R.N., Archer J.I., Crandon S., Zemanek J.A., Brown E.R., Neuzil K.M., Stephens D.S., Post D.J., Nayak S.U., Suthar M.S., Roberts P.C., Beigel J.H., Montefiori D.C. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep. Med. 2022;3 - PMC - PubMed

[8] Lyke K.E., Atmar R.L., Islas C.D., Posavad C.M., Szydlo D., Paul Chourdhury R., Deming M.E., Eaton A., Jackson L.A., Branche A.R., El Sahly H.M., Rostad C.A., Martin J.M., Johnston C., Rupp R.E., Mulligan M.J., Brady R.C., Frenck R.W., Jr., Bäcker M., Kottkamp A.C., Babu T.M., Rajakumar K., Edupuganti S., Dobrzynski D., Coler R.N., Archer J.I., Crandon S., Zemanek J.A., Brown E.R., Neuzil K.M., Stephens D.S., Post D.J., Nayak S.U., Suthar M.S., Roberts P.C., Beigel J.H., Montefiori D.C. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep. Med. 2022;3 - PMC - PubMed

[9] Parums D.V. Editorial: world health organization (WHO) variants of concern lineages under monitoring (VOC-LUM) in response to the global spread of lineages and sublineages of Omicron, or B.1.1.529, SARS-CoV-2. Med. Sci. Monit. 2022;28 international medical journal of experimental and clinical research. - PMC - PubMed

[10] Parums D.V. Editorial: world health organization (WHO) variants of concern lineages under monitoring (VOC-LUM) in response to the global spread of lineages and sublineages of Omicron, or B.1.1.529, SARS-CoV-2. Med. Sci. Monit. 2022;28 international medical journal of experimental and clinical research. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variant

Affiliations

Severe acute respiratory syndrome coronavirus 2 evolution: How mutations affect XBB.1.5 variant

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical